Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Rod S Taylor, Rebecca J. Taylor, Susan Bayliss, et al.
Gastroenterology (2020) Vol. 158, Iss. 6, pp. 1611-1625.e12
Open Access | Times Cited: 798

Showing 1-25 of 798 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1810
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1542-1556
Open Access | Times Cited: 1345
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1966-1986
Open Access | Times Cited: 1182
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1135
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1116
Liver cirrhosis
Pere Ginès, Aleksander Krag, Juan G. Abraldeṣ, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1359-1376
Closed Access | Times Cited: 942
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 450-456
Open Access | Times Cited: 925
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal, Mark L. Van Natta, Jeanne M. Clark, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1559-1569
Open Access | Times Cited: 702
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 642
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 637
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 573
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 1, pp. 101133-101133
Open Access | Times Cited: 530
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 522
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon, Björn Roelstraete, Hamed Khalili, et al.
Gut (2020) Vol. 70, Iss. 7, pp. 1375-1382
Open Access | Times Cited: 467
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper, Anna Martin, Sonja Lang, et al.
Clinical Research in Cardiology (2020) Vol. 110, Iss. 7, pp. 921-937
Open Access | Times Cited: 461
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 385
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 372
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 368
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Ferenc E. Mózes, Jenny Lee, Emmanuel Selvaraj, et al.
Gut (2021) Vol. 71, Iss. 5, pp. 1006-1019
Open Access | Times Cited: 357
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 354
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 334
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 280
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 260
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
Jenny Lee, Yasaman Vali, Jérôme Boursier, et al.
Liver International (2020) Vol. 41, Iss. 2, pp. 261-270
Open Access | Times Cited: 247
Page 1 - Next Page

Scroll to top